Puma Biotechnology/$PBYI
1D1W1MYTD1Y5YMAX
Capital at risk
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Ticker
- $PBYI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 179
- Headquarters
- Los Angeles, United States
- Website
- www.pumabiotechnology.com
PBYI Metrics
BasicAdvanced
$496M
19.06
$0.50
1.22
-
Price and volume
Market cap
$496M
Beta
1.22
52-week high
$9.74
52-week low
$4.37
Average daily volume
307K
Financial strength
Current ratio
2.912
Quick ratio
2.568
Long term debt to equity
0.032
Total debt to equity
0.035
Interest coverage (TTM)
8.65%
Profitability
EBITDA (TTM)
40.135
Gross margin (TTM)
74.86%
Net profit margin (TTM)
11.56%
Operating margin (TTM)
13.17%
Effective tax rate (TTM)
14.28%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
9.81%
Return on equity (TTM)
21.99%
Valuation
Price to earnings (TTM)
19.064
Price to revenue (TTM)
2.102
Price to book
3.54
Price to tangible book (TTM)
4.81
Price to free cash flow (TTM)
11.81
Free cash flow yield (TTM)
8.47%
Free cash flow per share (TTM)
0.813
Growth
Revenue change (TTM)
-2.86%
Earnings per share change (TTM)
-48.22%
3-year revenue growth (CAGR)
0.16%
3-year earnings per share growth (CAGR)
101.58%
10-year earnings per share growth (CAGR)
-24.17%
What the Analysts think about PBYI
Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.
Analyst projections of the future price of Puma Biotechnology stock.
PBYI Financial Performance
Revenues and expenses
PBYI Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBYI News
AllArticlesVideos
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
Business Wire3 days ago
Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference
Business Wire2 weeks ago
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 weeks ago
Funds containing PBYI
AllUSDGBPEUR
Fund name | Fund size | $PBYI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.